Ceftaroline fosamil, the prodrug form of the active metabolite ceftaroline, is a new broad-spectrum parenteral cephalosporin with antibacterial activity against the prevalent respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus. Bacterial resistance surveillance (5330 isolates) was conducted in the United States between 2008 and 2010 to assess the in vitro activity of ceftaroline and comparator antibacterial agents against invasive respiratory isolates of S. pneumoniae (3329 isolates), H. influenzae (1545 isolates), and M. catarrhalis (456 isolates). All organisms were cultured from patient infections in 71 US hospital laboratories and were submitted to a central reference monitor for broth microdilution testing by Clinical and Laboratory Standards Institute reference methods. Against S. pneumoniae, ceftaroline inhibited 98.7% of strains at the susceptible breakpoint of ≤0.25 µg/mL (50% minimum inhibitory concentration [MIC 50 ], 0.01 µg/mL; 90% MIC [MIC 90 ], 0.12 µg/mL) and was 16-fold more active than ceftriaxone (MIC 90 , 2 µg/mL). Among 70 ceftriaxone-resistant pneumococcal isolates, all were inhibited by ≤0.5 µg/mL of ceftaroline. Haemophilus influenzae (MIC 50 , ≤0.008 µg/mL; MIC 90 , 0.015 µg/mL) and M. catarrhalis (MIC 50 , 0.06 µg/mL; MIC 90 , 0.12 µg/mL) were very susceptible to ceftaroline regardless of β-lactamase production. Whereas the high-level of activity of ceftaroline was maintained against S. pneumoniae and H. influenzae from 2008 through 2010, increased rates of nonsusceptibility were observed for amoxicillin/clavulanate, erythromycin, and levofloxacin among S. pneumoniae and for trimethoprim/ sulfamethoxazole and azithromycin among H. influenzae. In summary, ceftaroline resistance surveillance (Assessing Worldwide Antimicrobial Resistance Evaluation [AWARE] Program) in the United States (2008)(2009)(2010) documented in vitro sustained potency and spectrum against Gram-positive and Gram-negative pathogens known to cause community-acquired bacterial pneumonia.
clindamycin, and co-trimoxazole were 37.1%, 20.3%, and 22.5%, respectively, among respiratory isolates of S. pneumoniae. Haemophilus influenzae was also frequently identified among patients hospitalized with CABP [5] , and the prevalence of β-lactamase-producing strains was 22% among H. influenzae respiratory isolates in the United States [6] . Likewise, CABP due to S. aureus, including methicillin-resistant S. aureus (MRSA), is increasingly common and carries a high rate of mortality [7] . Initial therapy of CABP should provide broad coverage against common causative organisms, including existing and emerging resistant phenotypes. As such, the initial treatment of CABP requires prescription of empiric combination therapy or the application of an agent with sufficient broad-spectrum coverage to include MDRSP and MRSA.
Ceftaroline fosamil (hereafter referred to as ceftaroline) is the prodrug form of the active metabolite ceftaroline, a new broad-spectrum cephalosporin that demonstrates in vitro activity against typical respiratory pathogens, including resistant Gram-positive pathogens such as MDRSP and MRSA and common Gram-negative pathogens such as M. catarrhalis, β-lactamase-producing H. influenzae, and many enteric Gram-negative bacilli (Escherichia coli and Klebsiella pneumoniae) [1, 6, [8] [9] [10] [11] . Ceftaroline was approved in 2010 by the US Food and Drug Administration (FDA) for the treatment of CABP [12, 13] and acute bacterial skin and skin structure infections (ABSSSIs) [14, 15] .
In this article, we review the results of a 3-year (2008-2010) US surveillance study of ceftaroline and comparators tested against a collection of 5330 clinical isolates of S. pneumoniae, H. influenzae, and M. catarrhalis cultured from patient infections (95% respiratory or bloodstream infection isolates) in 71 unique US hospitals. All testing was performed by reference broth microdilution (BMD) methods and categorical interpretations employed Clinical and Laboratory Standards Institute (CLSI) or FDA criteria [16] [17] [18] [19] .
MATERIALS AND METHODS

Surveillance Network and Organisms
The bacterial strains were collected from 71 medical centers representing all 9 US Census regions. Among a total of 5330 consecutively collected isolates processed between 2008 and 2010, 5080 (95%) were either respiratory tract or bloodstream infection isolates, including 3329 isolates of S. pneumoniae, 1545 of H. influenzae, and 456 of M. catarrhalis.
Each cultured organism was unique (1 isolate per patient per infectious episode). All testing was performed in a central reference laboratory ( JMI Laboratories, North Liberty, Iowa) under Good Laboratory Practices-and Clinical Laboratory Improvement Amendments-certified conditions.
Antimicrobial Susceptibility Testing
All organisms were tested for antimicrobial susceptibility by the CLSI BMD method [18] . Validated BMD panels and broth reagents utilized were manufactured by Thermo Fisher Scientific (formerly TREK Diagnostics). Comparator agents included those representing the most common classes of drugs used for treatment of the indicated pathogens for CABP. Ceftaroline and the following comparison agents were tested: ceftazidime, penicillin, ampicillin, amoxicillin/clavulanate, piperacillin/tazobactam, ceftriaxone, cefuroxime, meropenem, tetracycline, tigecycline, trimethoprim/sulfamethoxazole, clindamycin, erythromycin, azithromycin, clarithromycin, levofloxacin, moxifloxacin, vancomycin, and linezolid. Quality control (QC) strains were also tested and results indicated that proper test conditions and procedures were applied [19] . These organisms included the following ATCC QC strains: E. coli ATCC 25922; Pseudomonas aeruginosa ATCC 27853; S. aureus ATCC 29213; Enterococcus faecalis ATCC 29212; H. influenzae ATCC 49247 and ATCC 49766; and S. pneumoniae ATCC 49619. Susceptibility percentages and validation of QC results were based on breakpoints and ranges obtained from CLSI publications [18] [19] [20] (Table 1) . Breakpoint criteria for ceftaroline susceptibility were those indicated in the product package insert [16] for S. pneumoniae (≤0.25 µg/mL; no resistant breakpoint) and H. influenzae (≤0.12 µg/mL; no resistant breakpoint). For purposes of this study, we have categorized those strains of S. pneumoniae and H. influenzae for which ceftaroline MIC values were greater than the susceptibility breakpoint as nonsusceptible. No breakpoint has been established for M. catarrhalis. The QC limits for ceftaroline reference tests have been published by the CLSI [19, 21] . Of the QC MIC results, 99.5% were within established ranges.
RESULTS
Activity Against S. Pneumoniae
The activity of ceftaroline and 13 comparator agents against 3329 US isolates of S. pneumoniae are shown in Table 1 . Depending on the penicillin breakpoints used, this collection contained up to 21.1% penicillin-resistant strains (using CLSI criteria for penicillin [oral penicillin V]) [19] . Ceftaroline showed very potent activity (MIC 50 , 0.015 µg/mL; MIC 90 , 0.12 µg/mL) against penicillin-resistant S. pneumoniae, with 98.7% of all S. pneumoniae isolates inhibited by <0.25 µg/mL. Accordingly, ceftaroline was 8-to >64-fold more active than all comparators with the exception of tigecycline (MIC 90 , 0.06 µg/mL). Direct comparison of ceftaroline (MIC 90 , 0.12 µg/mL) with ceftriaxone for all S. pneumoniae tested illustrated a 16-fold potency advantage. Among 70 ceftriaxone-resistant strains of S. pneumoniae, all were inhibited by <0.5 µg/mL of ceftaroline. S188 • CID 2012:55 (Suppl 3) • Pfaller et al Similar to ceftriaxone, all of the β-lactams as well as tetracycline, trimethoprim/sulfamethoxazole, clindamycin, and erythromycin had compromised coverage of these contemporary US isolates of S. pneumoniae (Table 1) . Amoxicillin/clavulanate (83.0%) and penicillin (85.2%) exhibited low susceptibility rates. Only the fluoroquinolones (levofloxacin [99.2% susceptibility], vancomycin [100.0% susceptibility], and linezolid [>99.9% susceptibility]) showed comparably high in vitro activity at currently applied breakpoints (Table 1) .
Activity Against H. Influenzae and M. Catarrhalis
Ceftaroline demonstrated potent activity against 1545 isolates of H. influenzae (MIC 50 , ≤0.008 µg/mL; MIC 90 , 0.015 µg/mL) regardless of the β-lactamase capability of the tested strains (Table 1 ). All but 2 strains of H. influenzae were inhibited by ≤0.12 µg/mL of ceftaroline. This degree of activity and coverage (99.9% susceptibility) was comparable to that of amoxicillin/clavulanate (99.9% susceptibility), ceftriaxone (100.0% susceptibility), cefuroxime (99.2% susceptibility), meropenem (100.0% susceptibility), tetracycline (98.7% susceptibility), azithromycin (98.7% susceptibility), and levofloxacin (100.0% susceptibility) (see Table 1 ).
When tested against M. catarrhalis (443 isolates), ceftaroline demonstrated a potency that was comparable to that observed against S. pneumoniae (MIC 90 , 0.12 µg/mL) ( Table 1 ). All isolates except 1 (MIC, 1 µg/mL) were inhibited at a ceftaroline concentration of ≤0.25 µg/mL. Other tested antimicrobial agents had comparable activity at utilized breakpoints [19, 20] with complete or nearly complete (≥94.4% susceptibility) coverage for amoxicillin/clavulanate, ceftriaxone, cefuroxime, tetracycline, trimethoprim/sulfamethoxazole, erythromycin, and levofloxacin (Table 1) . β-Lactamase production was detected in M. catarrhalis isolates at a rate of 96.4%.
Three-Year (2008-2010) Trends in Decreased Susceptibility or Resistance Among US Isolates of S. Pneumoniae and H. Influenzae
The frequency of nonsusceptibility for ceftaroline against both S. pneumoniae and H. influenzae was extremely low (1.2%-1.5% and 0.0%-0.3%, respectively) and did not change significantly over the 3-year monitored interval (Table 2) . Similarly, the rates of resistance for most of the comparators remained stable for both organisms, with the exception of slight increases in resistance for erythromycin (38.4% to 41.7%) and levofloxacin (0.6% to 1.09%) for S. pneumoniae and trimethoprim/ sulfamethoxazole (19.4% to 24.4%) and azithromycin (0.8% to 1.4%) for H. influenzae (Table 2) .
DISCUSSION
Ceftaroline fosamil represents a new class of cephalosporin with anti-MRSA activity [10, 22] largely due to its truly b Minimum inhibitory concentration encompassing 50% and 90% of isolates tested, respectively. c Percent of isolates for which the MIC is greater than the susceptibility breakpoint are categorized as NS.
d Food and Drug Administration breakpoints were applied when available [16] . Streptrococcus pneumoniae, susceptibility ≤0.25 µg/mL, no R or I (intermediate) category; H. influenzae, susceptibility ≤0.12 µg/mL, no R or I category. e Criteria as published by the CLSI for penicillin parenteral (non-meningitis) [19] .
f Criteria as published by the CLSI for penicillin (oral penicillin V) [19] .
g Food and Drug Administration breakpoints were applied when available [17] .
h Based on β-lactamase production.
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• CID 2012:55 (Suppl 3) • Pfaller et al unique expanded Gram-positive activity against MRSA and MDRSP. Numerous published studies confirm a consensus MIC 90 value of 0.12-0.25 µg/mL against S. pneumoniae, with the highest MIC result rarely exceeding 0.5 µg/mL [1, 6, 8, [23] [24] [25] [26] [27] [28] [29] . These results were obtained from pneumococci collected from throughout the world, including the United States. The data presented herein provide further documentation of the excellent activity of ceftaroline when tested against significant collections of contemporary US pneumococcal isolates. Other compounds that exhibited excellent activity against pneumococci in the present study included levofloxacin (99.2% susceptible), linezolid (>99.9% susceptible), and vancomycin (100.0% susceptible). Many of the published reports have emphasized the potent activity of ceftaroline against penicillin-resistant, cefotaximeresistant, and MDR isolates of S. pneumoniae, including emerging serotype 19A strains [23, 24, 27, 30, 31] . Other pathogens associated with CABP, including H. influenzae and M. catarrhalis, are also inhibited by ceftaroline at concentrations <0.5 µg/mL (Table 1) . Notably, ceftaroline exhibits high activity against respiratory isolates of S. aureus (97.0% of strains inhibited by ≤1 µg/mL) and non-extended-spectrum β-lactamase phenotypes of E. coli and K. pneumoniae (>90.0% of strains inhibited by ≤0.5 µg/mL) [6] .
Ceftaroline has some activity against anaerobic bacteria, although it has little or no activity against Clostridium difficile, Bacteroides fragilis, or Prevotella spp. [32] . Although it is generally well tolerated, minor adverse events have included rash, nausea, vomiting, diarrhea, headache, and tendon pain [32] .
The favorable features of ceftaroline include avid binding to penicillin-binding protein 2a and 2 × ( penicillin-binding proteins) of MRSA and MDRSP, respectively [1, 8] , minimal disruption of normal bowel flora [32] , lack of antagonism with other agents used in combination [33] , and an in vitro postantibiotic effect against Gram-positive pathogens of 1-2 hours' duration [34] .
These features, coupled with documented efficacy of ceftaroline fosamil in the treatment of serious CABP [2, 13] , make this agent particularly attractive in the initial management of CABP patients requiring hospitalization and infected with potentially refractory pathogens such as MDRSP [35] . Presently, many of these types of serious CABP infections have required combination empiric or directed therapies [36, 37] , whereas ceftaroline fosamil may be applied as a single treatment entity. Clinical application of ceftaroline fosamil in the United States for the treatment of CABP will provide an important therapeutic option based on these most recent (2008-2010) surveillance study results (Tables 1 and 2 ). The continued evolution of respiratory pathogens with reduced susceptibility to established antimicrobial agents makes an agent such as ceftaroline fosamil a particularly welcome addition to our antimicrobial armamentarium.
Notes
